{"paper_id":"8829243d-1183-4ad3-baac-fbb0589a93cf","body_text":"Endometriosis is a common disorder, affecting ~10% of women worldwide. However, despite this high prevalence, treatment options are still very limited. Current treatments include surgery and hormone-based medications; however, these are often ineffective. As a result, large numbers of people are living with this debilitating condition. A new study reports early findings of a non-hormonal treatment that could be effective in endometriosis.\nReceptor tyrosine kinases (RTKs) might underlie some of the effects of endometriosis. Given that the FDA has approved pexidartinib (a tyrosine kinase inhibitor), Timothy Dunn and colleagues set out to determine whether this drug could be viable for use in endometriosis.\nThis is a preview of subscription content, access via your institution\nAccess options\nAccess Nature and 54 other Nature Portfolio journals\nGet Nature+, our best-value online-access subscription\n27,99 € / 30 days\ncancel any time\nSubscribe to this journal\nReceive 12 print issues and online access\n176,64 € per year\nonly 14,72 € per issue\nBuy this article\n- Purchase on SpringerLink\n- Instant access to the full article PDF.\n39,95 €\nPrices may be subject to local taxes which are calculated during checkout\nReferences\nOriginal article\nDunn, T. N. et al. Inhibition of CSF1R and KIT with pexidartinib reduces inflammatory signaling and cell viability in endometriosis. Endocrinology https://doi.org/10.1210/endocr/bqae003 (2024)\nRelated article\nGirling, J. E. Harnessing the inflammatory processes in endometriosis. Nat. Rev. Endocrinol. 20, 69–70 (2024)\nAuthor information\nAuthors and Affiliations\nCorresponding author\nRights and permissions\nAbout this article\nCite this article\nGreenhill, C. Targeting endometriosis. Nat Rev Endocrinol 20, 193 (2024). https://doi.org/10.1038/s41574-024-00959-z\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1038/s41574-024-00959-z","source_license":"CC0","license_restricted":false}